Tiziana Life Sciences PLC (TLSA)

Stock Price: $5.18 USD -0.07 (-1.33%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
GlobeNewsWire - 3 days ago

LONDON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics for on...

GlobeNewsWire - 5 days ago

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

GlobeNewsWire - 6 days ago

NEW YORK and LONDON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therape...

Benzinga - 1 week ago

Tiziana Life Sciences (NASDAQ: TLSA) shares are trading higher on Friday after news emerged the company has submitted a patent application covering the potential use of a nasally-administered ...

GlobeNewsWire - 1 week ago

LONDON and NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on th...

GlobeNewsWire - 1 week ago

NEW YORK and LONDON, July 31, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therap...

GlobeNewsWire - 1 week ago

NEW YORK and LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc the dual listed (NASDAQ:TLSA & UK AIMS:TILS) today announces its intention to apply for admission to listing ...

GlobeNewsWire - 1 week ago

NEW YORK and LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therap...

GlobeNewsWire - 2 weeks ago

LONDON and NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therap...

GlobeNewsWire - 2 weeks ago

NEW YORK and LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development o...

Bloomberg Technology - 3 weeks ago

Video: Tiziana CEO Says Don't Confuse Them With Tesla

Tiziana Life Sciences Plc is a dual-listed British biotech firm, says it's ridiculous to think investors confuse his company's ticker symbol with that of Tesla.

GlobeNewsWire - 3 weeks ago

LONDON and NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on th...

GlobeNewsWire - 3 weeks ago

NEW YORK and LONDON, July 16, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therap...

GlobeNewsWire - 3 weeks ago

NEW YORK and LONDON, July 15, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level 3 American Depositary R...

GlobeNewsWire - 3 weeks ago

NEW YORK and LONDON, July 15, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level 3 American Depositary R...

Zacks Investment Research - 3 weeks ago

As of late, it has definitely been a great time to be an investor in Tiziana Life Sciences PLC (TLSA).

GlobeNewsWire - 4 weeks ago

NEW YORK and LONDON, July 10, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing ta...

GlobeNewsWire - 1 month ago

This proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for develo...

GlobeNewsWire - 1 month ago

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

GlobeNewsWire - 1 month ago

LONDON and NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), the U.S. and U.K. biotechnology company that focuses...

GlobeNewsWire - 2 months ago

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

GlobeNewsWire - 2 months ago

NEW YORK and LONDON, May 29, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for on...

GlobeNewsWire - 2 months ago

NEW YORK and LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer, inflam...

GlobeNewsWire - 2 months ago

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

GlobeNewsWire - 2 months ago

Additional data to be presented validating the SPARE Model for Distant Metastasis Prediction utilizing the Company’s StemPrintER Platform Additional data to be presented validating the SPARE M...

GlobeNewsWire - 3 months ago

Combination of nanoparticle-Actinomycin D acting as an anti-viral treatment, with an anti-inflammatory agent may present a potential therapeutic option for COVID-19 patients Combination of nan...

GlobeNewsWire - 3 months ago

Nanoparticle Actinomycin formulation minimizes toxicity and enhances tolerability by slow release of drug to control Cmax in blood

GlobeNewsWire - 4 months ago

Company Has Filed Patent Application in Support of Treatment of COVID-19 Utilizing Anti-IL6R Via Inhaled Delivery Company Has Filed Patent Application in Support of Treatment of COVID-19 Utili...

Benzinga - 4 months ago

Tiziana Life Sciences PLC (NASDAQ: TLSA) shares were advancing strongly Wednesday following an announcement by the company regarding plans to develop one of its pipeline assets for treating CO...

Latest From StockTwits